Edition:
United Kingdom

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Capital Market

0.27USD
23 May 2018
Change (% chg)

$-0.01 (-3.40%)
Prev Close
$0.28
Open
$0.28
Day's High
$0.28
Day's Low
$0.27
Volume
57,621
Avg. Vol
393,696
52-wk High
$2.96
52-wk Low
$0.26

Chart for

About

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $18.00
Shares Outstanding(Mil.): 10.91
Dividend: --
Yield (%): --

Financials

  ANTH.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -9.69 -- --
ROI: -321.65 1.57 14.38
ROE: -434.34 2.43 16.07

BRIEF-Anthera Pharma's Board Approves Personnel Reorganization Plan

* ANTHERA PHARMACEUTICALS INC - BOARD APPROVED & COMMENCED A MANAGEMENT & ADMINISTRATIVE PERSONNEL REORGANIZATION PLAN

16 Apr 2018

Anthera to explore options after lead drug fails trial, shares slump

Anthera Pharmaceuticals Inc said on Monday it would evaluate all strategic options after its lead drug failed in a late-stage trial, sending its shares down 80 percent in premarket trading.

12 Mar 2018

UPDATE 1-Anthera to explore options after lead drug fails trial, shares slump

March 12 Anthera Pharmaceuticals Inc said on Monday it would evaluate all strategic options after its lead drug failed in a late-stage trial, sending its shares down 80 percent in premarket trading.

12 Mar 2018

BRIEF-Anthera Pharmaceuticals Reports Top Line Data From Result Phase 3 Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS REPORTS TOP LINE DATA FROM THE RESULT PHASE 3 CLINICAL STUDY OF SOLLPURA

12 Mar 2018

Anthera to explore options after lead drug's trial failure

March 12 Anthera Pharmaceuticals Inc said on Monday it would evaluate all strategic options after its lead drug failed in a late-stage trial.

12 Mar 2018

BRIEF-Anthera Pharma Files For Mixed Shelf Of Up To $100 Million

* ANTHERA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​ Source: (http://bit.ly/2G0f8YX) Further company coverage:

06 Mar 2018

BRIEF-Anthera Pharma Qtrly Net Loss Per Share Applicable To Common Stockholders $0.73

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 FOURTH QUARTER AND FISCAL YEAR FINANCIAL RESULTS

05 Mar 2018

BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study

* ANTHERA ANNOUNCES POSITIVE OUTCOME OF SECOND INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA: STUDY ON SCHEDULE FOR TOPLINE DATA THIS QUARTER

22 Jan 2018

BRIEF-683 Capital Management Reports 6.1 Pct Passive Stake In Anthera Pharma

* 683 CAPITAL MANAGEMENT, LLC REPORTS A 6.1 PERCENT PASSIVE STAKE IN ANTHERA PHARMACEUTICALS INC AS OF JAN 8 - SEC FILING Source text: (http://bit.ly/2mOAqQ5)

18 Jan 2018

BRIEF-Anthera Pharma Appoints Patrick Murphy As Senior Vice President, Manufacturing

* ANTHERA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF PATRICK MURPHY AS SENIOR VICE PRESIDENT, MANUFACTURING Source text for Eikon: Further company coverage:

03 Jan 2018

Earnings vs. Estimates